Theramex has entered into a definitive commercial agreement with Endoceutics for Intrarosa (Prasterone), the private pharmaceutical company disclosed on Thursday.
The agreement grants Theramex the license to commercialise Intrarosa in countries across Europe, Australia, Russia, as well as select countries within the Commonwealth of Independent States (CIS).
Intrarosa is a unique non-oestrogen prescription therapy that has been approved for the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women experiencing moderate to severe symptoms. VVA affects up to 50% of postmenopausal women, causing dryness, irritation, soreness, and dyspareunia (or pain during sexual activity).
Clinical trials showed that Intrarosa improved the structure of the vaginal tissues and reduced pain during sexual intercourse. Intrarosa was well-tolerated in the trials. It was approved by the US Food and Drug Administration (FDA) in November 2016 as a treatment of dyspareunia, while the European Medicines Agency (EMA) approved it in January 2018 for the treatment of VVA.
Terms of the deal were not disclosed but the countries included in the license agreement are: Australia, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Romania, Serbia, Slovakia, Slovenia, United Kingdom, the Russian Federation, Kazakhstan, and the Ukraine.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT